Journal article

Quantitative assessment of corpus callosum morphology in periventricular nodular heterotopia

Heath R Pardoe, Simone A Mandelstam, Rebecca Kucharsky Hiess, Ruben I Kuzniecky, Graeme D Jackson

Epilepsy Research | ELSEVIER SCIENCE BV | Published : 2015

Grants

Awarded by National Health and Medical Research Council


Awarded by National Institute of Neurological Diseases and Stroke (NINDS)


Awarded by Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)


Awarded by DOD ADNI (Department of Defense)


Funding Acknowledgements

Primary support for this study was provided by the National Health and Medical Research Council (project grant 318900), National Institute of Neurological Diseases and Stroke (NINDS) grant U01 NS053998, Finding a Cure for Epilepsy and Seizures (FACES) foundation, the Richard Thalheimer Philanthropic Fund, and Amazon Web Services Education in Research grants.Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Eurolmmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research a Development, LLC.; Johnson Et Johnson Pharmaceutical Research a Development LLC.; Medpace, Inc.; Merck Et Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Ihstitutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.